BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Corcept Therapeutics Incorporated ("Corcept†or the "Company†) (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025, inclusive (the "Class Period†). Corcept investors have until April 21, 2026 to file a lead plaintiff motion. The complaint filed in this class action alleges that throughout the Class Period, Defendants made materiall ...

Schrödinger (NasdaqGS:SDGR) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Company ParticipantsConor MacKay - Equity Research AssociateJaren Madden - Chief Corporate Affairs Officer and Head of Investor RelationsKaren Akinsanya - President, Head of Therapeutics R&D, and Partnerships Chief Strategy OfficerRamy Farid - CEORichie Jain - CFONone - Company RepresentativeNone - Company RepresentativeNone - Company RepresentativeNone - Company RepresentativeConference Call ParticipantsBrendan Smith - Director ...

Mirum Pharmaceuticals (NasdaqGM:MIRM) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Company ParticipantsAndrew McKibben - SVP of Strategic Finance and Investor RelationsCharles Wallace - Managing DirectorChris Peetz - CEOEric Bjerkholt - CFOJames Condulis - VP of Biotechnology Equity ResearchJoanne Quan - Chief Medical OfficerJoe Kim - Assistant VPJonathan Wolleben - Managing DirectorJoseph Thome - Managing DirectorRyan Deschner - Director of Equity ResearchConference Call ParticipantsBrian Skorney - ...

Mirum Pharmaceuticals (NasdaqGM:MIRM) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Company ParticipantsAndrew McKibben - SVP of Strategic Finance and Investor RelationsCharles Wallace - Managing DirectorChris Peetz - CEOEric Bjerkholt - CFOJames Condulis - VP of Biotechnology Equity ResearchJoanne Quan - Chief Medical OfficerJoe Kim - Assistant VPJon Wolleben - Managing DirectorJoseph Thome - Managing DirectorRyan Deschner - Director of Equity ResearchConference Call ParticipantsBrian Skorney - Senio ...

Schrödinger (NasdaqGS:SDGR) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Speaker7Thank you for standing by. Welcome to Schrödinger's conference call to review fourth quarter and full year 2025 financial results. My name is Rob. I'll be your operator for today's call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star, then 1 on your telepho ...

Soleno Therapeutics (NasdaqCM:SLNO) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Speaker1Good afternoon, thank you for standing by. Welcome to Soleno Therapeutics' fourth quarter and full year 2025 financial and operating results conference call and webcast. Currently, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. As a reminder, today's webcast is being recorded. I would now like to introduce Brian Ritchie of LifeSci Advisors. ...

Mirum Pharmaceuticals (NasdaqGM:MIRM) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Speaker5Good afternoon, and welcome to Mirum Pharmaceuticals' fourth quarter and full year 2025 conference call. My name is Elliot, and I'll be your operator today. All lines are currently in listen-only mode, and there'll be an opportunity for Q&A after management's prepared remarks. I'd now like to hand the conference over to Andrew McKibben, SVP of Strategic Finance and Investor Relations. Please go ahead.Speaker0Th ...

Revolution Medicines (NasdaqGS:RVMD) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Speaker15Good day, and thank you for standing by. Welcome to Revolution Medicines' fourth quarter 2025 earnings conference call. After the speaker's presentation, there will be a question-and-answer session. To ask a question during your session, you will need to press star 11 on your telephone. You will then hear an automated message advising that your hand is raised. To withdraw your question, please press star 11 aga ...

ACADIA Pharmaceuticals (NasdaqGS:ACAD) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Speaker11Thank you for standing by. My name is J.L., and I will be your conference operator today. At this time, I would like to welcome everyone to the ACADIA Pharmaceuticals Inc. fourth quarter earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press s ...

Group 1 - The article discusses the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies and offers a model portfolio of small and mid-cap stocks [1][2] - The service includes over 600 articles on biotech investing, live chat, and various analysis and news reports to assist healthcare investors [2] - A promotional offer is available for new subscribers, including a two-week free trial and a discounted annual subscription price [1] Group 2 - The previous discussion on Equillium (EQ) focused on its drug candidate EQ504 for ulcerative colitis (UC) [2] - The author emphasizes the importance of utilizing an applied science background to generate long-term value in the healthcare sector [2]